Actinium Pharmaceuticals Inc.

04/18/2024 | Press release | Distributed by Public on 04/18/2024 06:05

Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory[...]